Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 4/20 | 1.00 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.85 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1272548 | 1.00 | HRH1 (1.00) | HRH1CYP2A6CHRNA7TDP1L3MBTL1 | |
| SCHEMBL3531226 | 1.00 | HRH1 (1.00) | HRH1CYP2A6CHRNA7TDP1L3MBTL1 | |
| SCHEMBL11214933 | 1.00 | HRH1 (1.00) | HRH1CYP2A6CHRNA7TDP1L3MBTL1 | |
| SCHEMBL2673539 | 0.98 | HRH1 (0.96) | HRH1CYP2A6CHRNA7TDP1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL28646442 | 0.96 | HRH1 (0.93) | HRH1CYP2A6CHRNA7TDP1L3MBTL1 | |
| SCHEMBL1188053 | 0.92 | CYP2A6 (1.00) | HRH1CYP2A6CHRNA7TDP1L3MBTL1 | |
| SCHEMBL30393717 | 0.92 | CYP2A6 (1.00) | HRH1CYP2A6CHRNA7TDP1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL6286905 | 0.90 | CYP2A6 (0.96) | HRH1CYP2A6CHRNA7TDP1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL10678754 | 0.90 | CYP2A6 (0.96) | HRH1CYP2A6CHRNA7TDP1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL30682561 | 0.90 | CYP2A6 (0.96) | HRH1CYP2A6CHRNA7TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230109457-A1 | USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-04-06 | — | — | US | claimed |
| US-11351161-B2 | Use of CDK9 inhibitors to reduce cartilage degradation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-07 | — | — | US | claimed |
| US-20210008054-A1 | USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-01-14 | — | — | US | claimed |
| US-20200046726-A1 | USE OF CDK9 AND BRD4 INHIBITORS TO INHIBIT INFLAMMATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-13 | — | — | US | claimed |
| US-20190255034-A1 | USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-22 | — | — | US | claimed |
| US-10172844-B2 | Use of CDK9 inhibitors to reduce cartilage degradation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-01-08 | — | — | US | claimed |
| US-11691986-B2 | PTEFB inhibiting macrocyclic compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-04 | — | — | US | disclosed |
| US-20230109457-A1 | USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-04-06 | — | — | US | disclosed |
| US-20220281892-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-08 | — | — | US | disclosed |
| US-11351161-B2 | Use of CDK9 inhibitors to reduce cartilage degradation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-07 | — | — | US | disclosed |
| US-11254690-B2 | PTEFb inhibiting macrocyclic compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-02-22 | — | — | US | disclosed |
| US-11242356-B2 | PTEFb inhibiting macrocyclic compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2022-02-08 | — | — | US | disclosed |
| EP-3601253-B1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | BAYER AG (DE) | 2021-09-15 | — | — | EP | disclosed |
| WO-2003031419-A1 | SUBSTITUTED DIPHENYLOXAZOLES, THE SYNTHESIS THEREOF, AND THE USE THEREOF AS FLUORESCENCE PROBES | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| US-20020032206-A1 | Pharmaceutical compositions for prevention and treatment of central nervous system disorders | CALDWELL WILLIAM SCOTT (US) | 2002-03-14 | — | — | US | disclosed |
| US-5616716-A | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds | TARGACEPT, INC. | 1997-04-01 | — | — | US | disclosed |
| US-4743610-A | ENZYME INHIBITORS, MYOCARDIAL INFARCTION PREVENTION | AMERICAN CYANAMID COMPANY (US) | 1988-05-10 | — | — | US | disclosed |
| EP-0094080-B1 | PYRIDO(2,1-B)QUINAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1987-09-09 | — | — | EP | disclosed |
| US-4551460-A | ANTICOAGULANTS, CARDIOVASCULAR DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1985-11-05 | — | — | US | disclosed |
| EP-0094080-A2 | Pyrido(2,1-b)quinazoline derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11242356-B2 | PTEFb inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | HRH1 3177/4885CYP2A6 1592/4885CHRNA7 4879/4885 |
| US-20020032206-A1 | Pharmaceutical compositions for prevention and treatment of central nervous system disorders | PMP22, AANAT, CHAT | HRH1 330/4885CYP2A6 172/4885CHRNA7 13/4885 |
| US-20200046726-A1 | USE OF CDK9 AND BRD4 INHIBITORS TO INHIBIT INFLAMMATION | CDK9, BRD4, CDK19 | HRH1 3398/4885CYP2A6 4228/4885CHRNA7 4335/4885 |
| US-20220281892-A1 | NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS | PCLAF, PKD1, RHEB | HRH1 3427/4885CYP2A6 2496/4885CHRNA7 4881/4885 |
| US-20230109457-A1 | USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION | CDK9, CDK19, CDKN1A | HRH1 4607/4885CYP2A6 3399/4885CHRNA7 4684/4885 |
| US-20210008054-A1 | USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION | CDK9, CDK19, CDKN1A | HRH1 4607/4885CYP2A6 3399/4885CHRNA7 4684/4885 |
| US-20190255034-A1 | USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION | CDK9, CDK19, CDKN1A | HRH1 4607/4885CYP2A6 3399/4885CHRNA7 4684/4885 |
| US-11351161-B2 | Use of CDK9 inhibitors to reduce cartilage degradation | CDK9, CDK19, CDKN1A | HRH1 4607/4885CYP2A6 3399/4885CHRNA7 4684/4885 |
| US-10172844-B2 | Use of CDK9 inhibitors to reduce cartilage degradation | CDK9, CDK19, CDKN1A | HRH1 4607/4885CYP2A6 3399/4885CHRNA7 4684/4885 |
| US-11254690-B2 | PTEFb inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | HRH1 3177/4885CYP2A6 1592/4885CHRNA7 4879/4885 |
| US-11691986-B2 | PTEFB inhibiting macrocyclic compounds | PCLAF, PPIB, RHEB | HRH1 3177/4885CYP2A6 1592/4885CHRNA7 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.